Insmed Incorporated (INSM) Soars on Positive PAH Therapy Trial Results
Insmed Incorporated (NASDAQ:INSM) is among the 10 Best Growth Stocks Under $100 to Buy Now. The shares of Insmed Incorporated (NASDAQ:INSM) have witnessed a surge of about 32% in the course of five days following the success of Phase 2b of its once-daily pulmonary arterial hypertension (PAH) therapy, treprostinil palmitil inhalation powder (TPIP). The results were evaluated about 24 hours after the administration of the drug, showcasing a consistent benefit throughout the 24-hour dosing period.
Additionally, the company has revealed plans to initiate discussions with the U.S. Food and Drug Administration (FDA) to shape its Phase 3 trials roadmap. While this first Phase 3 trial will focus on pulmonary hypertension tied to interstitial lung disease by the year's end, the second trial is designed for PAH patients in the coming year. By 2032, the global market for pulmonary arterial hypertension is set to climb to $12.2 billion.
A biopharmaceutical research team taking notes in front of a laboratory's microscope.
The two anticipated phase 3 studies are enough to be excited about the company, yet there exists another breakthrough. Insmed Incorporated (NASDAQ:INSM) has finalized and submitted its New Drug Application (NDA) of brensocatib for treating patients with Non-cystic fibrosis bronchiectasis (NCFBE), with the date for review set for August 12, 2025. The company is indeed among the companies with high growth potential.
Insmed Incorporated (NASDAQ:INSM) is a New Jersey-based biopharmaceutical company that develops and markets therapies to treat patients with serious and rare diseases. With a global presence, the company is committed to transforming the lives of many.
While we acknowledge the potential of INSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
GoodRx (GDRX) Launches a New Subscription Service for Erectile Dysfunction Treatment
GoodRx Holdings, Inc. (NASDAQ:GDRX) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On June 10, GoodRx Holdings, Inc. (NASDAQ:GDRX) announced launching a new subscription service focused on erectile dysfunction (ED) treatment. The new service aims to innovate access to ED care by addressing common barriers such as high costs, social stigma, long wait times, and inconvenience. The key features of GoodRx Holdings, Inc.'s (NASDAQ:GDRX) new subscription service include an All-in-One Solution through which customers can book virtual consultations, get access to FDA-approved medicines, and also get discreet home deliveries. The subscription starts as low as $18 per month, with the final cost depending on the prescribed medication. We recognize that many men delay or entirely avoid treatment for ED due to stigma, costs, and the inconvenience of traditional healthcare pathways,' said Katelyn Pelak, VP and Head of Product at GoodRx Holdings, Inc. (NASDAQ:GDRX). A pharmacist assisting elderly customers with their GoodRX codes at a local pharmacy. Moreover, the company also released its latest study on ED, revealing nearly 1 in 3 men in the United States report difficulties with erections, but fewer than 14% use any treatment, largely due to insurance coverage gaps and social stigma. GoodRx Holdings, Inc. (NASDAQ:GDRX) is a leading US healthcare company that helps consumers save money on prescription medications by providing free access to drug price comparisons, digital coupons, and discounts at over 70,000 pharmacies nationwide. The company operates through a mobile app and website where users can get medications, access telemedicine services to consult doctors online and receive prescriptions without insurance. It is one of the best small-cap growth stocks to buy according to analysts. While we acknowledge the potential of GDRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
22 minutes ago
- Associated Press
Global User Experience Upgrade: How ZHGUI Exchange Enhances Trading Environment and Service Support
Colorado, USA, June 15, 2025 -- ZHGUI Exchange recently announced a comprehensive upgrade to its user experience framework, introducing multiple innovations across three key dimensions: technical performance, interface design, and service support. This upgrade encompasses an intelligent revamp of the user support system, multilingual localization of the trading interface, and cross-platform performance optimisation, aiming to deliver smoother, more efficient, and more secure trading flows for its expanding global user base. As its international clientele grows, ZHGUI continuously refines its products and services to bolster platform usability and user retention, further solidifying its leadership in the global crypto market. ZHGUI Exchange has placed particular emphasis on improving global user support. It now offers 24/7 customer service with real-time multilingual communication, ensuring that users receive timely assistance regardless of their location. Leveraging artificial intelligence and big data analytics, ZHGUI has launched an intelligent customer service system that enables users to swiftly obtain support via automated interactions, significantly enhancing service efficiency. On the user interface front, ZHGUI has implemented a thorough optimisation. The platform streamlines trading processes with a clearer, more intuitive design, allowing users to execute trades and monitor market conditions more quickly. 'Our aim is to let users focus on trading through a simple, intuitive design, improving the overall trading experience,' said Lily Chen, Chief Product Officer of ZHGUI. Cross-platform support of ZHGUI Exchange has also been strengthened with the release of tailored applications for both iOS and Android, ensuring consistent user experiences across devices. Whether on desktop or mobile, users can enjoy seamless trading capabilities, managing assets and executing trades anytime, anywhere. Furthermore, security remains paramount. ZHGUI employs industry-leading encryption technologies, real-time security monitoring, and multi-factor authentication (2FA) to safeguard user accounts and transaction data comprehensively. Transparency is bolstered through publicly accessible trading data and audit systems, enhancing the credibility and user trust of the platform. Through continuous technological innovation and service enhancement, ZHGUI not only provides a safer, more convenient, and more efficient trading environment for global users but also contributes to the healthy development of the cryptocurrency market. Looking ahead, ZHGUI is committed to further upgrading platform features to deliver increasingly personalised trading experiences. Contact Info: Name: Irfan Saiful Email: Send Email Organization: ZHGUI Cryptocurrency Ltd Website: Disclaimer: This press release is for informational purposes only. Information verification has been done to the best of our ability. Still, due to the speculative nature of the blockchain (cryptocurrency, NFT, mining, etc.) sector as a whole, complete accuracy cannot always be guaranteed. You are advised to conduct your own research and exercise caution. Investments in these fields are inherently risky and should be approached with due diligence. Release ID: 89162239 Should you detect any errors, issues, or discrepancies with the content contained within this press release, or if you need assistance with a press release takedown, we kindly request that you inform us immediately by contacting [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our expert team will be available to promptly respond and take necessary steps within the next 8 hours to resolve any identified issues or guide you through the removal process. We value the trust placed in us by our readers and remain dedicated to providing accurate and reliable information.
Associated Press
22 minutes ago
- Associated Press
DEA Delays MMJ Cannabis Research While Allowing Texas Ibogaine Studies Without Obstruction: The Tale of Two Schedule I Substances
Two Schedule I drugs. Two research tracks. One DEA double standard. MMJ BioPharma Cultivation's FDA sanctioned cannabis research has been stonewalled for seven years. Meanwhile, Texas launches state-funded ibogaine trials with full political support and zero DEA obstruction. Is federal drug policy about science or selective enforcement? WASHINGTON, DC / ACCESS Newswire / June 15, 2025 / The Drug Enforcement Administration (DEA) has spent the last seven years obstructing MMJ BioPharma Cultivation's federally lawful efforts to research cannabis derived medicine for devastating neurological diseases. Yet this week, the same Drug Enforcement Administration sits idly by as Texas Governor Greg Abbott signs SB 2308, a bold new law investing $50 million into clinical research of ibogaine, a Schedule I psychedelic with no FDA approval and known cardiotoxicity risks. The DEA hypocrisy is staggering. Two Schedule I Drugs, Two Opposite Realities Ibogaine and marijuana are both Schedule I substances - the most restrictive classification under the Controlled Substances Act. This means the DEA claims they have: And yet, while Texas is encouraged to pursue ibogaine trials through gifts, grants, and state matching funds, MMJ BioPharma has been trapped in a Kafkaesque limbo for attempting the same with cannabis-despite MMJ's direct alignment with the FDA's Investigational New Drug (IND) process, orphan drug designation, and a DEA-compliant manufacturing facility. 'Why is Texas allowed to bypass federal enforcement for psychedelic research while MMJ BioPharma Cultivation is targeted and delayed for developing cannabis-based therapies through the FDA?' stated Duane Boise CEO MMJ. The Texas Psychedelic Loophole: DEA Selective Enforcement? Under SB 2308, Texas will now: There has been no indication that the DEA intends to interfere with this psychedelic research initiative. In fact, Texas officials cite DEA coordination as merely a procedural formality. Compare that to MMJ BioPharma: Despite this, DEA attorneys - including those under internal ethics investigation - have argued to dismiss MMJ's claims and to keep the company locked out of cannabis-based drug development. So let's ask the obvious: Will the DEA block Texas next? Or are Schedule I drugs only 'dangerous' when researched by companies the DEA doesn't control? Veterans Deserve Science, Not Bureaucracy Both ibogaine and cannabis have shown promise in treating PTSD, opioid dependency, and neurodegenerative diseases, especially among U.S. veterans. But only one path is being respected by federal regulators: the one funded by politics, not science. 'Patients deserve real medicine, not political footballs,' said Duane Boise, CEO of MMJ International Holdings. The Inconvenient Truth: MMJ Followed the Law - And Paid the Price The contrast could not be more striking: If the DEA allows Texas to move forward unimpeded while continuing to obstruct MMJ's FDA-approved research, it will be a glaring admission of regulatory bias, abuse of discretion, and political favoritism. Congress, the courts, and the public must now ask: Is the DEA enforcing the law-or weaponizing it? If the DEA cannot respect the law, then the law must be used to dismantle the DEA. MMJ is represented by attorney Megan Sheehan. CONTACT: Madison Hisey [email protected] 203-231-8583 SOURCE: MMJ International Holdings press release
